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The molecular nature of a severe multisystemic disorder with a recurrent nonimmune hydrops fetalis was identiﬁed
as deﬁciency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase, the human orthologue of the yeast ALG1
gene (MIM 605907). The disease belongs to the group of congenital disorders of glycosylation (CDG) and is
designated as subtype CDG-Ik. In patient-derived serum, the total amount of the glycoprotein transferrin was
reduced. Moreover, a partial loss of N-glycan chains was observed, a characteristic feature of CDG type I forms.
Metabolic labeling with [6-3H]glucosamine revealed an accumulation of GlcNAc2-PP-dolichol and GlcNAc1-PP-
dolichol in skin ﬁbroblasts of the patient. Incubation of ﬁbroblast extracts with [14C]GlcNAc2-PP-dolichol and
GDP-mannose indicated a severely reduced activity of the b1,4-mannosyltransferase, elongating GlcNAc2-PP-dol-
ichol to Man1GlcNAc2-PP-dolichol at the cytosolic side of the endoplasmic reticulum.Genetic analysis of the patient’s
hALG1 gene identiﬁed a homozygous mutation leading to the exchange of a serine residue to leucine at position
258 in the hALG1 protein. The disease-causing nature of the hALG1 mutation for the glycosylation defect was
veriﬁed by a retroviral complementation approach in patient-derived primary ﬁbroblasts and was conﬁrmed by the
expression of wild-type and mutant hALG1 in the Saccharomyces cerevisiae alg1-1 strain.
Introduction
Glycosylation of proteins is one of the most widespread
forms of co- and posttranslational modiﬁcation that has
been found in eukaryotes, as well as in prokaryotes. In
eukaryotes, glycoproteins are located inside cells pre-
dominantly in membranes of the secretory and endocytic
pathway. Moreover, they are abundant in extracellular
ﬂuids and matrices. Glycan moieties attached to glyco-
proteins were shown to affect their folding and their
transport, as well as their biological activity and stability
(Spiro et al. 2002). The process of protein glycosylation
is essential for viability and normal development and
requires 1100 glycosyltransferases, glycosidases, and
transport proteins for sugar nucleotides (Helenius and
Aebi 2001; Trombetta 2003). So far, 14 different mo-
lecular causes for inherited deﬁciencies in this complex
metabolic pathway have been described in humans; these
are termed “congenital disorders of glycosylation”
(CDG) (Jaeken 2003; Thiel et al. 2003; Wu et al. 2003).
Received October 17, 2003; accepted for publication January 2,
2004; electronically published February 16, 2004.
Address for correspondence and reprints: Dr. Christian Ko¨rner,
Georg-August-Universita¨t Go¨ttingen, Biochemie II, Heinrich-Du¨ker-
Weg 12, D-37073 Go¨ttingen, Germany. E-mail: ckoerne@gwdg.de
*These authors contributed equally to this work.
 2004 by The American Society of Human Genetics. All rights reserved.
0002-9297/2004/7403-0016$15.00
CDG comprise a group of multisystemic diseases with
mostly severe psychomotor and mental retardation. Bi-
ochemically, the disorders are characterized by defective
glycosylation of proteins caused by mutations in genes
required for the biosynthesis of N-linked oligosacchar-
ides. CDG are subdivided into two groups. CDG type
I (CDG-I) comprise defects that affect biosynthesis of
dolichol-linked oligosaccharides in the cytosol or the en-
doplasmic reticulum (ER), as well as defects involving
the transfer of oligosaccharides onto nascent glycopro-
teins. CDG type II (CDG-II) encompass all defects of
further trimming and elongation of N-linked oligosac-
charides in the ER and the Golgi (Aebi et al. 1999).
Here we describe a molecular defect in glycoprotein
biosynthesis that results in a new type of CDG-I in
humans (termed “CDG-Ik”). The defective biosynthesis
is due to the faulty transfer of mannosyl residues from
GDP-Man to GlcNAc2-PP-dolichol, which is catalyzed
by the enzyme hALG1 at the cytosolic side of the ER.
Methods
Patient
The patient described here is the second child (P.B.)
in the original case report (de Koning et al. 1998). Ul-
trasound analysis at the 30th wk of pregnancy revealed
fetal hydrops and hepatosplenomegaly. Pregnancy was
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interrupted at the 35th wk because of bradycardia. The
severely hydropic boy showed multiple dysmorphic fea-
tures with a large fontanelle, hypertelorism, microgna-
thia, hypogonadism, contractures, areﬂexia, cardiomy-
opathy, and multifocal epileptic activity. The patient died
at 2 wk of age. Isoelectric focusing (IEF) of serum trans-
ferrin revealed a typical CDG-I pattern with the ap-
pearance of disialo- and asialotransferrin. Normal ac-
tivity of phosphomannomutase excluded CDG-Ia.
IEF and SDS/PAGE of Serum Transferrin
IEF and SDS/PAGE of serum transferrin were per-
formed as described elsewhere (Niehues et al. 1998).
Cell Lines and Cell Culture
Fibroblasts from the patient and the controls were
maintained at 37C under 5% CO2 in Dulbecco’s Mod-
iﬁed Eagle Medium (DMEM [Gibco BRL]), which con-
tained 10% fetal calf serum (FCS [PAN Biotech]). The
ecotropic packaging cell line FNX-Eco (ATCC) and the
amphotropic packaging cell line RetroPack PT67 (Clon-
tech) were cultured in DMEM containing 10% FCS—
which was heat-inactivated at 56C for 30 min—at 37C
under 5% CO2, unless otherwise stated.
Analysis of Dolichol- and Protein-Derived
Oligosaccharides
Fibroblasts derived from the controls and the pa-
tient were grown and metabolically labeled with
[2-3H]mannose for 30 min at 37C. Dolichol- and pro-
tein-linked oligosaccharides were extracted, released,
and analyzed by high-performance liquid chromatog-
raphy (HPLC), as described elsewhere (Ko¨rner et al.
1998).
TLC Analysis of Short Dolichol-Linked
Oligosaccharides
Prior to the experiment (60 h), 3.6# 106 control- or
patient-derived ﬁbroblasts were plated onto 100-mm
cell-culture dishes. Cells were labeled for 60 min in the
presence of 1 mCi [6-3H]glucosamine (29.0 Ci/mmol
[Amersham Biosciences]) in DMEM containing 2% di-
alyzed FCS, 0.5 mM glucose, and 0.5 mM mannose.
Fibroblasts were scrapped in methanol, and the short
dolichol-linked oligosaccharides were extracted and sep-
arated by thin-layer chromatography (TLC), as de-
scribed elsewhere (Ko¨rner et al. 1998).
Enzyme Assays
To determine ALG1-encoded mannosyltransferase ac-
tivity, GlcNAc2-PP-Dol was used as the glycosyl accep-
tor. Analysis of subsequent mannose elongation steps
was performed with Man1GlcNAc2-PP-Dol as the ac-
ceptor. The reactions contained the following, in a ﬁnal
volume of 0.06 ml: [14C]GlcNAc2-PP-Dol (4,000 cpm)
or Man1[
14C]GlcNAc2-PP-Dol (4,000 cpm), 0.13%
Nonidet P40, 10 mM MgCl2, 0.9 mM DTT, 0.14 mM
Na-EDTA, 19 mMTris-HCl (pH 7.2), 1 mMGDP-Man,
and solubilized enzyme (equivalent to 0.05 mgmembrane
protein). Incubations were performed at 37C for 12
min. The reaction was stopped by the addition of
chloroform:methanol to give a ratio of chloroform:
methanol:water of 2:1:1 (by volume) and was pro-
cessed further by phase separation (Sharma et al. 1982)
by use of an upper phase of chloroform:methanol:water
of 1:32:48 (by volume) and by collecting both lower
phase and inter phase. The solubilized extract was ob-
tained from a particulate ﬁbroblast fraction, prepared
as described elsewhere (Knauer and Lehle 1994; Thiel
et al. 2002), except that membranes were suspended in
20 mM Tris (pH 7.2), 10 mM MgCl2, and 1 mM DTT.
Solubilization was performed at a protein concentration
of 7 mg/ml and 1% Nonidet NP40. Preparation of
[14C]GlcNAc2-PP-dolichol and Man1[
14C]GlcNAc2-PP-
dolichol glycosyl acceptors was performed as described
elsewhere (Thiel et al. 2003).
Mutation Analysis
Total RNA was extracted from ﬁbroblasts and leu-
kocytes from the controls, the patient, and the patient’s
parents by use of the RNAeasy kit (Qiagen). First-strand
cDNA was synthesized from 0.5 mg of total RNA with
Omniscript reverse transcriptase (Qiagen) and the
primer R1 (5′-CAAAGCTTCCCGGGTCACAG-3′). In
the ﬁrst round of PCR, the cDNA was ampliﬁed using
the primers F1 (5′-GATCCCAATACAGTAACAGC-
TTT-3′) and R1 by use of the HotStar Taq polymerase
kit (Qiagen), with a preincubation at 95C for 15 min
followed by 28 cycles with 1 min at 94C, 0.5 min at
55C, and 3 min at 72C. Further ampliﬁcation was
performed with the nested primers F2 (5′-GGGAACCG-
CGTCCACTTCTC-3′) and R2 (5′-CACTGGGAGGT-
GCTGCTCG-3′). Reverse transcriptase PCR products
were run on 1% agarose gels. The 1,593-bp fragment
was prepared with the QIAquick PCR puriﬁcation kit
(Qiagen) and subcloned into the pGEM-T-Easy vector
(Promega). Sequence analyses of the PCR products and
the plasmids were performed by dye-determined cycle
sequencing with the primers pUC M13 forward and
pUC M13 reverse (Stratagene), F2, R2, R3 (5′-CTCAG-
GAGTTTCTGGTCCGGT-3′), and R4 (5′-GTGGAGC-
CGGAGGTCGGTC-3′) on an Applied Biosystems
model 373A automated sequencer.
Genomic DNAwas prepared from control and patient
ﬁbroblasts, as well as from blood leukocytes of the par-
ents, by use of standard procedures (Maniatis 1989).
PCR was performed with the primers gen-F1 (5′-GATG-
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Figure 1 IEF pattern and SDS-PAGE of serum transferrin. Sera
from a control, patient P.B., and a patient with CDG-Ia were analyzed
by IEF (upper panel) and SDS-PAGE, followed by western blotting
(lower panel) and immunodetection of transferrin. “Tetrasialo,” “di-
sialo,” and “asialo” on the upper panel indicate transferrin forms with
four, two, or no sialic acid residues. The numerals “2,” “1,” and “0”
in the lower panel indicate transferrin forms with two, one, or zero
oligosaccharide chains.
TGGCTGGGCACCCCA-3′) and gen-R1 (5′-CTGGCA-
GGGGTGAGGAGAAC-3′), as described above. Nested
PCR was performed using the primers gen-F2 (5′-GGG-
AGCCTGCAGGCCTCG-3′) and gen-R2 (5′-AGGTGC-
CCGTCACACCAACC-3′), resulting in a 301-bp frag-
ment. The PCR products were analyzed on a 1% agarose
gel and prepared as described above. Sequence analyses
were performed using primers gen-F3 (5′-GGAGATGC-
CTCTCCTGGGTC-3′).
Site-Directed Mutagenesis
A 1.6-kb fragment of a wild-type ALG1-cDNA rep-
resenting the coding sequence (nt 107–nt 1486) was am-
pliﬁed by PCR, by use of primers F2 and R2. The re-
sulting fragment was puriﬁed and cloned into the
pGEM-T-Easy vector (pGEM-T-Easy–wild-type). The
mutation C773T was inserted into the cDNA by use of
the QuickChange site-directed mutagenesis kit (Strata-
gene), according to the manufacturer’s instructions,with
the primers Mut773-A (5′-GGAGCGGTTGGCCTTC-
ACG-3′) and Mut773-B (5′-CGTGAAGGCCAACCG-
CTCC-3′) to obtain plasmid pGEM-T-Easy-Pat. Wild-
type and patient ALG1 cDNA was subcloned into the
MoMuLV-derived vector pLNCX2 (Clontech).
Retroviral Complementation
Ecotropic FNX-Eco cells (5 # 105) were seeded onto
dishes (60-mm diameter) 1 d before transfection. Tran-
sient transfection by FuGENE6 reagent was performed
according to the manufacturer’s protocol (Roche), with
1 mg of LNCX2 vector (mock), LNCX2 wild type, and
LNCX2 patient. Further procedures were performed as
described elsewhere (Thiel et al. 2002). The supernatant
with the amphotropic retroviral particles was used to
transfect patient and control ﬁbroblasts. After infection
of the ﬁbroblasts, the medium was replaced by DMEM,
containing 10% heat-inactivated FCS with geneticin (335
mg/ml [Gibco BRL]). Selection was performed for 10 d.
Yeast Genetics
The cDNAs of the human alg1 mannosyltransferases
from the controls and the patient, cloned into the p-
LNCX2 vector (Clontech), were isolated as NotI 1.4-
kbp fragments and ligated into the NotI site of the yeast
shuttle vector pNEV-N, under the control of the PMA1
promotor, to give pNEV-hALG1-Wt and pNEV-ALG1-
Pat, respectively. Plasmids were transformed into the
alg1-1 yeast strain (MATa ura3-52) by use of standard
techniques (Gietz and Schiestl 1991). Yeast cells were
grown in YNBDmedium (0.67% yeast nitrogen dropout
ura, 2% glucose).
Growth Complementation of alg1 Yeast Cells
Transformants were grown in selective liquid medium
overnight at 25C, and 3 ml of serial 10-fold dilutions
were spotted on agar plates, starting at 104 cells, and
were incubated at 25C or 36C for 4 d.
In Vivo Labeling of Dolichol-Linked Oligosaccharides
in Yeast
Yeast cells were grown at 25C to midlogarithmic
phase in selective medium and were shifted to 36C for
40 min. Subsequent labeling with [2-3H]mannose at
36C, extraction, and analysis of dolichol-linked oli-
gosaccharides were performed as described elsewhere
(Knauer and Lehle 1999).
Metabolic Labeling of Carboxypeptidase Y (CPY)
Yeast cells were grown at 25C in selective medium
to midlogarithmic phase. Cells were harvested, resus-
pended in fresh medium, adapted to 25C or 36C for
30 min, and labeled with 75 mCi [35S] methionine/cys-
teine (Pro-mix [Amersham Biosciences]) for 45 min.
Preparation of cell lysates, immunoprecipitation of CPY,
and analysis by SDS-PAGE were performed as described
elsewhere (Knauer and Lehle 1999).
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Figure 2 Analysis of protein- and dolichol-derived oligosaccharides in CDG-Ik. Fibroblasts of a control (B) and the patient (D) were
metabolically labeled with [2-3H]mannose for 30 min, [2-3H]glycans were released from equal amounts of the glycoprotein fraction by PNGase
F digestion and were size fractionated by HPLC. M9 and M9G1 refer to the positions of GlcNAc2Man9 and GlcNAc2Man9Glc1 standards,
respectively. Control- (A) and patient-derived (C) ﬁbroblasts (in equal amounts) were metabolically labeled with [2-3H]mannose for 30 min.
The [2-3H]oligosaccharides were released from the dolichol-PP moiety by mild acid hydrolysis and were size fractionated by HPLC. M9G3 refers
to the position of a GlcNAc2Man9Glc3 standard.
Results
Partial Lack of Entire N-Linked Oligosaccharide Side
Chains in Serum Transferrin
IEF of serum transferrin is the standard diagnostic
procedure for CDG. Previous data for the index patient
revealed a partial loss of sialic acids leading to an in-
crease of di- and asialotransferrin at the expense of tetra-
sialotransferrin, indicating a case of CDG-I. To exclude
a diagnosis of CDG-Ia, which is the most frequent type
of CDG-I, the activity of phosphomannomutase 2, the
enzyme deﬁcient in CDG-Ia, was determined and was
found to be normal (de Koning et al. 1998).
Our analysis of the transferrin IEF conﬁrmed the data
published for patient P.B. (de Koning et al. 1998) and
demonstrated, moreover, that the total amount of trans-
ferrin was reduced in the serum of the patient, compared
with serum of a control person and a CDG-Ia patient
(ﬁg. 1, upper panel). The mass of the protein was de-
termined by SDS-PAGE (ﬁg. 1, lower panel). The pres-
ence of faster-migrating transferrin forms indicated the
loss of one or both of the two N-linked oligosaccharide
side chains, which are normally present in transferrin.
Deﬁciency of phosphomannose isomerase, which leads
to a comparable IEF pattern of transferrin in CDG-Ib,
was excluded, since enzyme activity determined in pa-
tient ﬁbroblasts was normal (data not shown).
Accumulation of Shortened Dolichol-Linked
Oligosaccharides in Patient-Derived Fibroblasts
First, to investigate the molecular mechanism of the
glycosylation defect, we attempted to study the transfer
of GlcNAc2Man9Glc3 moieties from dolichol onto newly
synthesized glycoproteins, which is catalyzed by the oli-
gosaccharyltransferase complex. Control- and patient-
derived ﬁbroblasts were metabolically labeled with
[2-3H]mannose, followed by extraction of total gly-
coproteins. N-glycan chains from equal amounts of gly-
coproteins were released by peptide:N-glycosidase F
(PNGase F) treatment and subsequently were analyzed
by HPLC (ﬁg. 2B and 2D). The oligosaccharides released
from newly synthesized glycoproteins of controls and
the patient eluted mainly at positions corresponding to
GlcNAc2Man9Glc1 and GlcNAc2Man9 standards, re-
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Figure 3 TLC analysis of [6-3H]glucosamine-labeled short dol-
ichol-linked oligosaccharides. Fibroblasts from a control (A) and
from patient P.B. (B) were metabolically labeled for 60 min with
[6-3H]glucosamine. After extraction of the short lipid-linked oligo-
saccharide fraction with chloroform:methanol (3:2), further analysis
was performed by TLC on silica gel 60 plates with chloroform:
methanol:water (65:25:4) as solvent. The position of the origin and
the positions of a [14C]GlcNAc2-PP-dolichol standard and a
Man1[
14C]GlcNAc2-PP-dolichol standard are indicated as GN2 and
GN2M1, respectively (C).
spectively. In four independent experiments, no signiﬁ-
cant difference in the amount of labeled oligosaccharides
was observed between the patient and the controls.
These results indicate that, at least under the experi-
mental conditions, sufﬁcient dolichol-linked oligosac-
charides in patient ﬁbroblasts are transferred onto newly
synthesized glycoproteins with a normal activity of
oligosaccharyltransferase.
Next, we investigated the size of dolichol-linked oli-
gosaccharides by metabolic labeling of ﬁbroblasts from
a control and the patient with [2-3H]mannose for 30
min, followed by extraction with chloroform:methanol:
water (10:10:3), release of the glycan moieties by mild
acid hydrolysis, and subsequent size fractionation of the
oligosaccharides by HPLC. The majority of dolichol-
linked oligosaccharides from the control and the patient
eluted at the position of a GlcNAc2Man9Glc3 standard
(ﬁg. 2A and 2C), indicating the formation of full-length
dolichol-linked oligosaccharides. Radioactivity eluting
in fractions 1–6 (e.g., ﬁg. 2C) represents [2-3H]mannose
that is occasionally carried over into the chloroform:
methanol:water (10:10:3) fraction during extraction of
dolichol-linked oligosaccharides.
For CDG-Ii [MIM 607906], it was shown (Thiel et
al. 2003) that a defect in one of the early steps of dol-
ichol-linked oligosaccharide biosynthesis leads to an ac-
cumulation of short dolichol-linked oligosaccharides
that escape the extraction procedure described above.
Moreover, defects in the initiating steps of dolichol-
linked oligosaccharide biosynthesis, such as the addi-
tion of the two glucosamine residues and the ﬁrst man-
nose residue, are missed by metabolic labeling with
[2-3H]mannose. Therefore, we labeled ﬁbroblasts from
a control and the patient for 60 min in the presence of
[6-3H]glucosamine, extracted the cells with chloroform:
methanol (3:2), and analyzed the extract by TLC (ﬁg. 3).
Besides nonmigrating radioactivity at the origin in the
control (ﬁg. 3A) and the patient (ﬁg. 3B) extracts, we
observed two additional peaks in the case of the patient
(ﬁg. 3B; peak 1 and peak 2). Peak 1 migrated with
GlcNAc2-PP-dolichol from a standard mixture contain-
ing GlcNAc2-PP-dolichol and Man1GlcNAc2-PP-doli-
chol (ﬁg. 3C). Peak 2 is supposed to be dolichol-PP-
GlcNAc1, which migrates faster due to its more hydro-
phobic nature.
Deﬁciency of GDP-Mannose:GlcNAc2-PP-Dolichol
b1,4-Mannosyltransferase (hAlg1) in Patient-Derived
Fibroblasts
The analysis of dolichol-linked oligosaccharides re-
vealed a predominant accumulation of GlcNAc2-PP-dol-
ichol and a minor accumulation of GlcNAc1-PP-dolichol
in ﬁbroblasts of the patient. A comparable accumulation
pattern of biosynthetic intermediates of dolichol-linked
oligosaccharides has been described for the temperature-
sensitive alg1-1 mutant from Saccharomyces cerevisiae,
in which the GDP-mannose:GlcNAc2-PP-dolichol b1,4-
mannosyltransferase is defective at the restrictive tem-
perature (Huffacker and Robbins 1982). To determine
whether elongation of GlcNAc2-PP-dolichol is impaired
in the patient, an in vitro assay was established by in-
cubating microsomal extracts from control and patient
ﬁbroblasts with GDP-mannose and [14C]GlcNAc2-PP-
dolichol. An extension of the newly synthesized glycan
up to Man5[
14C]GlcNAc2-PP-dolichol was observed in
presence of the microsomal extract from control ﬁbro-
blasts but not from ﬁbroblasts of patient P.B. (ﬁg. 4A
and 4B).
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Figure 4 In vitro determination of hALG1 and hALG2 activity. Microsomal extracts from ﬁbroblasts of a control (A, C) and the patient
(B, D) were incubated for 10 min with either [14C]GlcNAc2-PP-dolichol (A, B) or with Man1[
14C]GlcNAc2-PP-dolichol (C, D), respectively, in
the presence of GDP-mannose. Dolichol-linked oligosaccharides were extracted from the incubation mixture and were treated by mild acid hy-
drolysis, and the released oligosaccharides were separated by HPLC. The positions of a GlcNAc2-standard (GN2) and Man1–5GlcNAc2 (GN2M1–5)-
standards are marked by arrows.
Next, we investigated the ability of control and pa-
tient cell extracts to elongateMan1GlcNAc2-PP-dolichol,
which is catalyzed by the hALG2-encoded a1,3 man-
nosyltransferase. The reaction catalyzes the transfer of
the second mannosyl residue in the dolichol-linked oli-
gosaccharide assembly. Fibroblast extracts from a con-
trol and from patient P.B. were incubated in the presence
of GDP-mannose and Man1[
14C]GlcNAc2-PP-dolichol.
We found that both cell extracts were able to elongate
the oligosaccharide chain up to Man5 [
14C]GlcNAc2-PP-
dolichol (ﬁg. 4C and 4D). These ﬁndings demonstrate
that the transfer of the ﬁrst mannosyl residue to
GlcNAc2-PP-dolichol, which is catalyzed by hALG1, is
impaired in case of the patient.
Detection of a Homozygous Missense Mutation in the
hALG1 Gene
Sequencing of the hALG1 cDNA (accession number
BAA90748 [NCBI Entrez Database]) revealed homo-
zygosity for a C773T transition in the case of the patient
(data not shown). The C773T transition causes the sub-
stitution of serine residue 258 with a leucine residue.
The mutation was conﬁrmed on the level of genomic
DNA. Both parents were shown to be heterozygous for
the C773T transition mutation on the cDNA, as well as
on the genomic level (data not shown).
Retroviral Expression of Wild-Type hALG1
Complements for GDP-Man:GlcNAc2-PP-Dolichol
Mannosyltransferase Deﬁciency in the Patient
To conﬁrm that the C773T transition mutation in the
hALG1 gene is the disease-causing mutation in the pa-
tient, we expressed hALG1 wild-type cDNA (ﬁg. 5B),
as well as the hALG1 cDNA carrying the C773T mu-
tation (ﬁg. 5C) in patient-derived ﬁbroblasts, by use of
a retroviral expression system. The effect of the retro-
viral vector alone was investigated in patient ﬁbroblasts,
as well as control ﬁbroblasts (ﬁg. 5A and 5D). TLC
analysis of extracts from [6-3H]glucosamine-labeled pa-
tient ﬁbroblasts expressing the retroviral vector alone
(ﬁg. 5A) showed a major peak corresponding to a Dol-
PP-GlcNAc2 standard and a second peak that is sup-
posed to be Dol-PP-GlcNAc1, which is not present in
control ﬁbroblasts (ﬁg. 5D). Retroviral transduction of
the wild-type hALG1 cDNA, but not of the C773T mu-
tant hALG1 cDNA, led to normalization of dolichol-
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Figure 5 Retroviral transduction of patient ﬁbroblasts with wild-
type hALG1 cDNA leads to complementation of the hALG1 deﬁciency.
Dolichol-PP-[3H]GlcNAc2 and dolichol-PP-[
3H]GlcNAc1 were extracted
with chloroform:methanol (3:2) from [6-3H]glucosamine-labeled con-
trol ﬁbroblasts expressing the retroviral vector alone (D) and from pa-
tient ﬁbroblasts, which were either transduced with the retroviral vector
alone (A), the wild-type cDNA (B), or the C773T hALG1 cDNA (C).
Further analysis was performed by TLC. The elution position of a
[14C]GlcNAc2-PP-dolichol standard and the origin (dotted line) are
indicated.
linked oligosaccharide biosynthesis in the patient, dem-
onstrating that the hALG1 deﬁciency causes the biochem-
ical defect in the patient and that the C773T mutation
causes inactivity of hALG1.
Wild-Type hALG1 Complements for the Defect in an
S. Cerevisiae alg1 Mutant Strain
To conﬁrm the complementation results in patient ﬁ-
broblasts, we introduced cDNAs encoding wild-type
hALG1 or the hALG1 C773T transition mutation into
the temperature-sensitive alg1-1 yeast strain. We found
that only transformation with the wild type but not with
the mutant hALG1 cDNA led to normalization of dol-
ichol-linked oligosaccharide biosynthesis in alg1-1 cells
(ﬁg. 6A), when analyzed by metabolic labeling with
[2-3H]mannose.
Complementation was also evident when the growth
behavior in the alg1-1 strain was investigated (ﬁg. 6B).
At the permissive temperature of 25C, alg1-1 cells that
were transformed with either the vector alone, the
hALG1 C773T mutant cDNA, or the hALG1 wild-type
cDNA showed comparable growth (ﬁg. 6, left panel).
At the nonpermissive temperature of 36C, correction
of the growth phenotype occurred only by transfor-
mation with wild-type hALG1 cDNA, but not with the
hALG1 C773T mutant (ﬁg. 6, right panel).
Next, we analyzed the glycosylation of the vacuolar
glycoprotein CPY (ﬁg. 6C). At the permissive temper-
ature, the glycosylation state of CPY was comparable
between alg1-1 cells either transformed with the vector
alone (lane 3), the hALG1 C773T cDNA (lane 2), or
the hALG1 wild-type cDNA (lane 1). The glycosylation
state of CPY is severely reduced in the alg1-1 strain at
the nonpermissive temperature of 36C because of a re-
duced transfer of truncated oligosaccharides onto the
newly synthesized protein (ﬁg. 6C, lane 6). Again, only
transformation of the alg1-1 strain with the wild type
(lane 4), but not with the C773T hALG1 cDNA (lane
5), led to normalization of CPY glycosylation, as oc-
curring in yeast wild-type cells (lane 7). Taken together,
these results conﬁrm, ﬁrst, that the C773T transition in
the hALG1 gene is the disease-causing mutation in
CDG-Ik and, second, that the isolated gene is indeed the
human orthologue to the yeast ALG1 gene.
Discussion
In a patient suffering frommultiple dysmorphic features,
hypertelorism, micrognathia, hepatosplenomegaly,
hypogonadism, contractures, areﬂexia, cardiomyopathy,
and multifocal epileptic activity (de Koning et al. 1998),
we determined a new molecular defect in the biosyn-
thesis of N-linked glycans. The defect in this new dis-
order, termed “CDG-Ik,” affecting an early step of dol-
ichol-linked oligosaccharide biosynthesis catalyzed by
the ALG1-encoded mannosyltransferase gene, was in-
dependently identiﬁed in two other patients with CDG
(T. Marquardt, personal communication).
Dolichol-linked oligosaccharide biosynthesis com-
prises a series of reactions by which, in a stepwise, or-
dered manner, two GlcNAc and ﬁve mannose residues
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Figure 6 Defects in dolichol-linked oligosaccharide biosynthesis (A), growth (B), and CPY glycosylation (C) in the alg1-1 yeast mutant
are complemented by expression of wild-type hALG1. A, Biosynthesis of dolichol-linked oligosaccharides was investigated in an alg1-1 strain
transformed with the wild-type hALG1 cDNA (left panel) or the hALG1 cDNA encoding the C773T mutation (right panel). Yeast cells were
metabolically labeled with [2-3H]mannose for 30 min, [2-3H] oligosaccharides were released from the dolichol moiety by mild acid hydrolysis
and further analyzed by HPLC. M1–M8 and G3 refer to Man1–8GlcNAc2 and Glc3Man9GlcNAc2 standards, respectively. B, Growth of yeast
alg1-1 cells either transformed with wild-type hALG1 cDNA, the C773T hALG1 or the expression vector was investigated under permissive
(25C, left panel) and nonpermissive temperature (36C, right panel). C, The glycosylation status of CPY is shown at the permissive temperature
(25C, left panel) and at the nonpermissive temperature (36C, right panel). Yeast cells were metabolically labeled with 35S-methionine for 30
min, and CPY was immunoprecipitated and analyzed by SDS-PAGE. The position of the mature form of CPY in wild-type yeast cells (mCPY)
and in the complemented alg1-1 cells are indicated on the right. Molecular weight standards are indicated on the left.
are added from nucleotide sugar donors to dolichol-
phosphate by glycosyltransferases on the cytosolic side
of the ER. After the translocation of Man5GlcNAc2-PP-
dolichol into the lumen of the ER, the oligosaccharide
moiety is further elongated to Glc3Man9GlcNAc2-PP-
dolichol, with Dol-P-Man and Dol-P-Glc as donor sub-
strates (Snider and Rogers 1984). The molecular defect
of the CDG-Ik patient affects the ALG1-encoded man-
nosyltransferase, catalyzing the transfer of the ﬁrst b1,4-
linked mannose residue onto the dolichol-bound chi-
tobiose residue at the outer leaﬂet of the ER, causing
the accumulation of GlcNAc2-PP-dolichol. Accumula-
tion of GlcNAc1-PP-dolichol, the biosynthetic precursor
of GlcNAc2-PP-dolichol, was also observed. This is
probably caused by feedback inhibition of the preceding
reaction resulting from the accumulation of GlcNAc2-
PP-dolichol, which interferes with a so-far-unknown en-
zyme catalyzing the elongation of GlcNAc1-PP-dolichol.
A comparable accumulation of GlcNAc2-PP-dolichol
and GlcNAc1-PP-dolichol for the temperature-sensitive
S. cerevisiae alg1-1 strain has been described elsewhere.
In yeast, deﬁciency ofALG1 leads to underglycosylation
of glycoproteins and cell death (Huffacker and Robbins
1982). The cDNA for the human orthologue of the yeast
ALG1 encodes a transmembrane protein with 464
amino acids containing several regions highly conserved
between yeast and humans (Takahashi et al. 2000). In
the case of the patient with CDG-Ik, we identiﬁed ho-
mozygosity for a C773T transition mutation in hALG1
at the mRNA and genomic DNA levels, whereas the
patient’s parents were heterozygous carriers of the mu-
tation. The mutation leads to replacement of a serine
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by a leucine residue at position 258 in the hALG1 pro-
tein. To prove the disease-causing nature of the C773T
mutation in the hALG1 gene, we expressed the wild-
type and the mutant hALG1 cDNA in patient-derived
ﬁbroblasts and in an S. cerevisiae alg1-1 strain, respec-
tively. In both cases, only the wild-type cDNA comple-
mented for the ALG1 deﬁciency, but not the C773T
mutation.
The serine residue at position 258 in the hAlg1 pro-
tein is conserved in the mouse and is replaced by a
threonine residue in Drosophila melanogaster, as well
as in S. cerevisiae, indicating the importance of the hy-
droxyl group. Computer-assisted protein structure anal-
ysis (TMpred) did not predict phosphorylation or O-
glycosylation of serine 258. The hALG1 protein is
predicted to have four transmembrane domains. Serine
258 is part of a loop, 222 amino acids in length, located
in the lumen of the ER. This would indicate that the
mutation does not directly affect either the binding sites
for the substrates or the catalytic sites that are supposed
to reside in the cytosolic domain. Instead, the Ser258Leu
mutation causes a conformational change of the hAlg1
protein in the patient.
The comparable HPLC size patterns of dolichol-
linked oligosaccharides in the chloroform:methanol:
water (10:10:3) fraction in control and patient ﬁbro-
blasts metabolically labeled with [2-3H]mannose points
to the leaky nature of the hALG1 deﬁciency in the pa-
tient. Manifestation of the defect may be restricted to
tissues, such as liver or pancreas, with high rates of
glycoprotein biosynthesis.
The biosynthesis of dolichol-linked oligosaccharides
is routinely investigated by metabolic labeling of cells
with [2-3H]mannose and analysis of the glycan moieties
in the fraction extracted with chloroform:methanol:
water (10:10:3). Similar to the metabolic defect in pa-
tients with CDG-Ii, in which the Alg2-mediated elon-
gation of the dolichol-linkedMan1GlcNAc2 trisaccharide
is deﬁcient, the metabolic defect in patients with CDG-
Ik would have escaped detection if just the routine pro-
tocol for dolichol-linked oligosaccharide analysis had
been applied. Early biosynthetic intermediates of doli-
chol-linked oligosaccharides are seldom (and poorly) la-
beled with [2-3H]mannose. Moreover, they are extracted
with chloroform:methanol (3:2) preceding extraction
with chloroform:methanol:water (10:10:3). Therefore,
we recommend that, in the growing number of patients
with a CDG-I IEF pattern for transferrin of unknown
origin, the ﬁbroblasts should be metabolically labeled
with [6-3H]glucosamine and the chloroform:methanol
(3:2) extract should be analyzed for dolichol-linked sugar
residues.
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